Bimagrumab

比玛卢单抗

Report date: 2025/10/28 20:00:08

Base Information

Drug NameBimagrumab
Drug Alias Name比戈卢单抗Bimagrumabum比马鲁人单抗BYM-338LY-3985863
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionActivin receptor type-2B inhibitors
TargetsActivin receptor type-2B
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[20] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMorphosys AgNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesVersanis Bio IncEli Lilly And CompanyMassachusetts General Hospital
Inactive CompaniesNovartis Pharma AgLilly Suzhou Pharmaceutical Co Ltd
Active IndicationsOverweightObesity
Inactive IndicationsDiabetes Mellitus, Type 2SarcopeniaPulmonary Disease, Chronic Obstructive +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG